StockData
10x Genomics, Inc. logo

10x Genomics, Inc. (TXG) income statement

TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30111% above fair value
$57.07+0.77 (+1.37%)

Close on Nov 18, 2026Market cap $7.44BP/E –Yield –

10x Genomics, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
71.9%
Operating margin
-11.7%
Net margin
-10.8%
Return on equity, FY2025
-5.8%

Financial strength

Current ratio
5.12
Debt to equity
–
Debt to assets
–
Cash to current liabilities
374.9%

Valuation

P/E ratio
–
Price to sales
12.02
Price to book
8.87
Dividend yield
–

See a number that looks wrong?